NCT03703492View on ClinicalTrials.gov

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 3, 2019

Primary Completion Date

January 2, 2024

Study Completion Date

January 2, 2024

Conditions
Breast CancerDuctal Carcinoma in Situ - Category
Interventions
DRUG

(18F)FES

"18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: \[18F\]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors"

DRUG

Gadobenate dimeglumine

Gadolinium-based intravenous contrast agent used for the MRI portion of this study

Trial Locations (1)

53705

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT03703492 - Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS | Biotech Hunter | Biotech Hunter